|
Fast Facts About Genzyme Corporation
CEO:
|
Henri A. Termeer
President 1983, CEO 1985, Chairman 1988
|
Founded:
|
1981
|
2008 Revenues:
|
$4.6 billion
|
2008 R & D Spending:
|
$750 million
|
Employees Worldwide:
|
More than 11,000
|
Headquarters:
|
Cambridge, MA
|
Exchange and Symbol:
|
Nasdaq, GENZ
|
Areas of Focus:
|
Genetic Diseases, Cardiometabolic & Renal , Hematologic Oncology, Biosurgery, Transplant, Genetics/Diagnostics
|
|
|
|
Top Products, based on FY 2008 Revenue:
|
Product Name
|
Disease/Condition
|
Revenue 2008
|
Cerezyme® (imiglucerase for injection)
|
Gaucher disease
|
$1.2 billion
|
Sevelamer
|
renal disease
|
$678 million
|
Fabrazyme® (agalsidase beta)
|
Fabry disease
|
$494 million
|
Synvisc® (hylan G-F 20)
|
osteoarthritis of the knee
|
$263 million
|
|
|
Key Pipeline Products:
|
Product Name
|
Disease/Condition
|
alemtuzumab (Campath®)
|
multiple sclerosis
|
mipomersen
|
high-risk hypercholesterolemia
|
Genz-112638 oral therapy
|
Gaucher disease
|
International Presence:
|
Genzyme has more than 85 locations in over 40 countries, including 17 manufacturing facilities and 9 genetic testing laboratories; the company's products are available in nearly 100 countries.
|
Charitable Contributions, FY 2008:
|
Global product donations, $144 million; U.S. cash contributions, $15.5 million
|
|
Home
